Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

CNS 2Dermatologic 1

Conditions

Neuroblastoma 2Melanoma 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Buthionine Sulfoximine × Clear all
NCT00002730 2024-11-20

Chemotherapy in Treating Children With Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
CNS

Neuroblastoma

NCT00005835 2023-04-10

BSO

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
31 enrolled
CNS

Neuroblastoma

NCT00661336 2015-03-13

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

Duke University

Phase 1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡